We found that the treatments with cHP1-4 alone do not alter the AChE activity in the in vitro AD model and that their relatively lower concentrations (0.1–50 μM) are ineffective against Aβ-induced AChE activity (data not shown). The gene discussed is ACHE; the disease is Alzheimer disease.